Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX9930 Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
2020-004403-14Phase 2Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing BCX9930 monotherapy with Placebo (2 arms). Primary endpoint: Part 1 primary efficacy endpoint. Started Jul 2021; status: terminated.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2020-004403-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004403-14.